España
India
Italia
대한민êµ
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Aldeyra Therapeutics
ALDX
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$4.89
0.01000
0.20%
Pre-Market: 6:50 PM EDT
Get Report
Comment
Aldeyra Therapeutics (ALDX) Forecast
News
Earnings
Aldeyra Therapeutics (ALDX) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Aldeyra Therapeutics (NASDAQ:ALDX) Stock
Aldeyra Therapeutics Stock (NASDAQ: ALDX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, November 18, 2024
Market-Moving News for November 18th
Benzinga Newsdesk
Aldeyra Therapeutics shares are trading highe...
Benzinga Newsdesk
Aldeyra Therapeutics Announces FDA Acceptance...
Benzinga Newsdesk
Thursday, October 03, 2024
Aldeyra Therapeutics Has Resubmitted New Drug...
Benzinga Newsdesk
Friday, August 09, 2024
HC Wainwright & Co. Reiterates Buy on Aldeyra...
Benzinga Newsdesk
Thursday, August 08, 2024
Aldeyra's New Eye Drug Shows Positive Results In FDA-Approved Study, Stock Jumps Over 30%
Vandana Singh
Aldeyra Therapeutics shares are trading highe...
Benzinga Newsdesk
Aldeyra Therapeutics Achieves Primary Endpoin...
Benzinga Newsdesk
Trading Halt: Halted at 6:55:00 a.m. ET - Tra...
Benzinga Newsdesk
Wednesday, August 07, 2024
Aldeyra Therapeutics Schedules Conference Cal...
Benzinga Newsdesk
Friday, August 02, 2024
HC Wainwright & Co. Reiterates Buy on Aldeyra...
Benzinga Newsdesk
Thursday, June 13, 2024
Aldeyra Therapeutics Wraps Up Phase 3 Trial E...
Benzinga Newsdesk
Wednesday, May 08, 2024
Aldeyra Therapeutics Enrolls First Patient in...
Benzinga Newsdesk
Monday, May 06, 2024
Oppenheimer Reiterates Outperform on Aldeyra ...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Aldeyra...
Benzinga Newsdesk
Thursday, April 25, 2024
Aldeyra Therapeutics Highlights Recent Precli...
Benzinga Newsdesk
Thursday, April 04, 2024
Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
Avi Kapoor
Wednesday, April 03, 2024
Aldeyra Therapeutics shares are trading highe...
Benzinga Newsdesk
Oppenheimer Upgrades Aldeyra Therapeutics to ...
Benzinga Newsdesk
Tuesday, April 02, 2024
HC Wainwright & Co. Reinstates Buy on Aldeyra...
Benzinga Newsdesk
Thursday, March 28, 2024
Aldeyra Therapeutics shares are trading highe...
Benzinga Newsdesk
Aldeyra Therapeutics Disclosed Clinical Devel...
Benzinga Newsdesk
Tuesday, March 05, 2024
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
Thursday, January 04, 2024
Aldeyra Therapeutics Reports Advancement Of R...
Benzinga Newsdesk
Thursday, December 21, 2023
On December 21, 2023, Aldeyra Therapeutics An...
Benzinga Newsdesk
Tuesday, December 19, 2023
Positive News For Skin Health: Aldeyra Therapeutics' ADX-629 Achieves Key Milestones in Atopic Dermatitis Study
Vandana Singh
Market-Moving News for December 19th
Benzinga Newsdesk
Aldeyra Therapeutics' Phase 2 Trial Of ADX-62...
Benzinga Newsdesk
Monday, December 18, 2023
Aldeyra Therapeutics Schedules Conference Cal...
Benzinga Newsdesk
Tuesday, November 28, 2023
FDA Rejects Aldeyra Therapeutics' Dry Eye Disease Candidate, Asks For Additional Study
Vandana Singh
Monday, November 27, 2023
Aldeyra Therapeutics Shares To Resume Trade A...
Benzinga Newsdesk
Aldeyra Therapeutics Receives Complete Respon...
Benzinga Newsdesk
Wednesday, November 01, 2023
Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
What's Going On With Aldeyra Therapeutics Stock?
Erica Kollmann
Aldeyra Will Receive A Option Fee Of $1M And ...
Benzinga Newsdesk
Aldeyra Therapeutics shares are trading highe...
Benzinga Newsdesk
Reported Earlier, Aldeyra Therapeutics Enters...
Benzinga Newsdesk
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
Market-Moving news for November 1st
Benzinga Newsdesk
Thursday, October 19, 2023
10% Owner of Aldeyra Therapeutics Makes $4.45M Sale
Benzinga Insights
Tuesday, October 17, 2023
Citigroup Maintains Buy on Aldeyra Therapeuti...
Benzinga Newsdesk
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
Benzinga Insights
Oppenheimer Downgrades Aldeyra Therapeutics t...
Benzinga Newsdesk
Monday, October 16, 2023
Crude Oil Moves Lower; Consolidated Communications Shares Jump
Lisa Levin
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
Nasdaq Gains 1%; Charles Schwab Earnings Top Views
Lisa Levin
Dow Surges Over 200 Points; Empire State Manufacturing Index Falls In October
Lisa Levin
Aldeyra Therapeutics Shares Resumed Trade The...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch